ROBERT ROBINSON: Open Payments
NPI 1518622380 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,192 in 71 payments from 15 companies in 2025. Trend: 2023 $586 · 2024 $1,107 · 2025 $1,192
Food & beverage: $1,188Education: $4
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 13 | $288 |
| Neurocrine BioSciences, Inc. | 11 | $194 |
| Vanda Pharmaceuticals Inc. | 11 | $153 |
| ABBVIE INC. | 12 | $144 |
| Lundbeck LLC | 4 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Corium, LLC | 5 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $33 |
Products named: ARISTADA, INGREZZA, FANAPT, VRAYLAR, REXULTI, CAPLYTA, Azstarys, COBENFY.
Industry payments across AL — which companies pay providers there.
